Ipsen licenses Sutro ADC in $900m deal

CAR-T Digest - August 2020

2 Apr 2024: Ipsen licenses Sutro ADC in $900m deal

Ipsen expands oncology pipeline through a licensing agreement with Sutro Biopharma for STRO-003, an ADC targeting ROR1
ROR1 is a protein present in malignant cells, offering the potential for targeted cancer therapy
STRO-003 is touted for its “best-in-class” potential, competing with other ROR1-targeted therapies
Other ROR1-targeted therapies include zilovertamab vedotin (MK-2140) from MSD and NBE-002 from Boehringer Ingelheim
STRO-003 stands out for its stability and exatecan payloads, potentially reducing off-target side effects